Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.82 |
| ▸ | EYA2 | O00167 | 1/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | ACE | P12821 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL224117 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL247531 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL30569658 | 1.00 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL668797 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10632169 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10937476 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2471967 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL11053686 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL6418284 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10906870 | 0.97 | TDP1 (0.78) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887814-A | Nucleic acid molecule line regulation and control method based on endogenous glutathione | 王富安 | 2024-04-16 | — | — | CN | claimed |
| US-20200330579-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | LIFFEY BIOTECH LIMITED (IE) | 2020-10-22 | — | — | US | claimed |
| US-20200113993-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | Pogona, LLC (US) | 2020-04-16 | — | — | US | claimed |
| US-12023377-B2 | Vaccine for use in the prophylaxis and/or treatment of a disease | INPROTHER APS (DK) | 2024-07-02 | — | — | US | disclosed |
| US-20240148860-A1 | VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE | INPROTHER APS (DK) | 2024-05-09 | — | — | US | disclosed |
| EP-3425382-B1 | SAMPLE SEPARATING IMPLEMENT AND SAMPLE ANALYZING DEVICE | MERCK LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-117887814-A | Nucleic acid molecule line regulation and control method based on endogenous glutathione | 王富安 | 2024-04-16 | — | — | CN | disclosed |
| EP-3236251-B1 | BIOMOLECULAR ANALYSIS APPARATUS | MERCK LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11919231-B2 | Three-dimensional printed organs, devices, and matrices | Prellis Biologics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240067990-A1 | POLYMERIC MICELLE COMPOSITIONS | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-02-29 | — | — | US | disclosed |
| CN-113564158-B | DNA primer, CRISPR/Cas12a system comprising same and kit | 卢青松 | 2024-02-20 | — | — | CN | disclosed |
| WO-2001016324-A2 | METHODS AND COMPOSITIONS OF A NOVEL SERINE PROTEASE INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1078077-A1 | NUCLEIC ACIDS AND PROTEINS FROM PINEAPPLE STEM | Cortecs (UK) Limited (GB) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000014253-A1 | NUCLEIC ACIDS AND PROTEINS FROM PINEAPPLE STEM | CORTECS (UK) LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000001847-A1 | COMBINED CANCER MARKER | UNIVERSITY OF LEEDS (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5917031-A | HEATING MIXTURE OF AT LEAST DEOXYCYTIDINE 5'-TRIPHOSPHATE OR DEOXYGUANOSINE 5'-TRIPHOSPHATE AND HEAT STABLE POLYMERASE FOR TIME FORMING POLYNUCLEOTIDES; SOLUTION HAS NO TEMPLATES OR PRIMERS | TAIKO PHARMACEUTICAL CO., LTD. (JP) | 1999-06-29 | — | — | US | disclosed |
| EP-0815252-A1 | GENE THERAPY FOR TRANSPLANTATION AND INFLAMMATORY OR THROMBOTIC CONDITIONS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| EP-0802258-A2 | Method of synthesizing polydeoxyribonucleotides, method of synthesizing chromosomal DNA and method of producing chromosomes | Taiko Pharmaceutical Co., Ltd. (JP) | 1997-10-22 | — | — | EP | disclosed |
| CN-1159755-A | Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders | OREAL (FR) | 1997-09-17 | — | — | CN | disclosed |
| WO-1996030532-A1 | GENE THERAPY FOR TRANSPLANTATION AND INFLAMMATORY OR THROMBOTIC CONDITIONS | NOVARTIS AG (CH) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023377-B2 | Vaccine for use in the prophylaxis and/or treatment of a disease | CD4, TSLP, ICOS | ADRA2A 3693/4885TDP1 2186/4885EYA2 3093/4885 |
| US-20240148860-A1 | VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE | CD4, TSLP, ICOS | ADRA2A 3693/4885TDP1 2186/4885EYA2 3093/4885 |
| US-20200113993-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | DNPEP, SI, IAPP | ADRA2A 4737/4885TDP1 2538/4885EYA2 3148/4885 |
| US-20200330579-A1 | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF | DNPEP, SI, IAPP | ADRA2A 4737/4885TDP1 2538/4885EYA2 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.